Merck Digital Sciences Studio Announces Second Cohort

On Monday November 20th, Merck (NYSE: MRK) announced the second biopharmaceutical cohort of the Merck Digital Sciences Studio (MDSS), a collaboration between Merck, Merck Global Health Innovation Fund, Northpond Ventures, McKesson Ventures, Microsoft for Startups, and New Jersey Innovation Institute.

The 10-month startup accelerator program empowers members with direct investments from Merck Global Health Innovation Fund, Northpond Ventures, and McKesson Ventures to enable the generation of innovative digital technologies for drug discovery and development.

The startup cohort will focus on important and disruptive bio-technical approaches in artificial intelligence (AI) and machine learning (ML), with expertise and tools from clinical scientists to continue Merck’s purpose to use the power of leading-edge science to save and improve lives.

Read the full announcement and learn more about the 12 companies selected to join this collaborative cohort here.